Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia

Pietro Bulian; Riccardo Bomben; Michele Dal Bo; Antonella Zucchetto; Francesca Maria Rossi; Massimo Degan; Federico Pozzo; Tamara Bittolo; Vanessa Bravin; Tiziana D’Agaro; Michaela Cerri; Annalisa Chiarenza; Kari G. Chaffee; Adalgisa Condoluci; Giovanni D’Arena; Michele Spina; Francesco Zaja; Gabriele Pozzato; Francesco Di Raimondo; Davide Rossi; Giovanni Del Poeta; Gianluca Gaidano; Tait D. Shanafelt; Valter Gattei

doi:10.3324/haematol.2017.170340

Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia

Pietro Bulian, Riccardo Bomben, Michele Dal Bo, Antonella Zucchetto, Francesca Maria Rossi, Massimo Degan, Federico Pozzo, Tamara Bittolo, Vanessa Bravin, Tiziana D’Agaro, Michaela Cerri, Annalisa Chiarenza, Kari G. Chaffee, Adalgisa Condoluci, Giovanni D’Arena, Michele Spina, Francesco Zaja, Gabriele Pozzato, Francesco Di Raimondo, Davide RossiGiovanni Del Poeta, Gianluca Gaidano, Tait D. Shanafelt, Valter Gattei

Hematology

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	e443-e446
Journal	Haematologica
Volume	102
Issue number	11
DOIs	https://doi.org/10.3324/haematol.2017.170340
State	Published - Oct 27 2017

ASJC Scopus subject areas

Hematology

Access to Document

10.3324/haematol.2017.170340

Cite this

Bulian, P., Bomben, R., Dal Bo, M., Zucchetto, A., Rossi, F. M., Degan, M., Pozzo, F., Bittolo, T., Bravin, V., D’Agaro, T., Cerri, M., Chiarenza, A., Chaffee, K. G., Condoluci, A., D’Arena, G., Spina, M., Zaja, F., Pozzato, G., Di Raimondo, F., ... Gattei, V. (2017). Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. Haematologica, 102(11), e443-e446. https://doi.org/10.3324/haematol.2017.170340

Bulian, P, Bomben, R, Dal Bo, M, Zucchetto, A, Rossi, FM, Degan, M, Pozzo, F, Bittolo, T, Bravin, V, D’Agaro, T, Cerri, M, Chiarenza, A, Chaffee, KG, Condoluci, A, D’Arena, G, Spina, M, Zaja, F, Pozzato, G, Di Raimondo, F, Rossi, D, Del Poeta, G, Gaidano, G, Shanafelt, TD & Gattei, V 2017, 'Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia', Haematologica, vol. 102, no. 11, pp. e443-e446. https://doi.org/10.3324/haematol.2017.170340

@article{0c53de8af93c465e8832b9b78df4faee,

title = "Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia",

author = "Pietro Bulian and Riccardo Bomben and {Dal Bo}, Michele and Antonella Zucchetto and Rossi, {Francesca Maria} and Massimo Degan and Federico Pozzo and Tamara Bittolo and Vanessa Bravin and Tiziana D{\textquoteright}Agaro and Michaela Cerri and Annalisa Chiarenza and Chaffee, {Kari G.} and Adalgisa Condoluci and Giovanni D{\textquoteright}Arena and Michele Spina and Francesco Zaja and Gabriele Pozzato and {Di Raimondo}, Francesco and Davide Rossi and {Del Poeta}, Giovanni and Gianluca Gaidano and Shanafelt, {Tait D.} and Valter Gattei",

note = "Funding Information: 1Clinical and Experimental Onco-Hematology Unit, IRCCS Centro di Riferimento Oncologico, Aviano, Italy;2Division of Hematology – Department of Translational Medicine – Amedeo Avogadro University of Eastern Piedmont, Novara, Italy;3Division of Hematology, Ferrarotto Hospital, Catania, Italy;4Department of Hematology, Mayo Clinic, Rochester, MN, USA;5Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland;6IRCCS, Referral Cancer Center of Basilicata, Potenza, Italy;7Oncologia Medica A IRCCS, Centro di Riferimento Oncologico, Aviano, Italy;8Clinica Ematologica, Centro Trapianti e Terapie Cellulari {"}Carlo Melzi{"} DISM, Azienda Ospedaliera Universitaria S. Maria Misericordia, Udine, Italy; 9Department of Internal Medicine and Hematology, Maggiore General Hospital, University of Trieste, Italy and 10Division of Hematology, S. Eugenio Hospital and University of Tor Vergata, Rome, Italy Funding: supported in part by the Associazione Italiana Ricerca Cancro (AIRC), Investigator Grants IG-17622; Progetto Giovani Ricercatori no. GR-2011-02347441, no. GR-2011-02346826, no. GR-2011-02351370, Ministero della Salute, Rome, Italy; Ricerca clinica, traslazionale, di base, epidemiologica e organizzativa, Regione Friuli Venezia Giulia (“Linfo-Check” Project), Trieste, Italy; Associazione Italiana contro le Leucemie, linfomi e mielomi (AIL), Venezia Section, Pramaggiore Group, Italy; Fondazione per la Vita di Pordenone, Italy; 5x1000 Intramural Program, Centro di Riferimento Oncologico, Aviano, Italy.",

year = "2017",

month = oct,

day = "27",

doi = "10.3324/haematol.2017.170340",

language = "English (US)",

volume = "102",

pages = "e443--e446",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "11",

}

TY - JOUR

T1 - Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia

AU - Bulian, Pietro

AU - Bomben, Riccardo

AU - Dal Bo, Michele

AU - Zucchetto, Antonella

AU - Rossi, Francesca Maria

AU - Degan, Massimo

AU - Pozzo, Federico

AU - Bittolo, Tamara

AU - Bravin, Vanessa

AU - D’Agaro, Tiziana

AU - Cerri, Michaela

AU - Chiarenza, Annalisa

AU - Chaffee, Kari G.

AU - Condoluci, Adalgisa

AU - D’Arena, Giovanni

AU - Spina, Michele

AU - Zaja, Francesco

AU - Pozzato, Gabriele

AU - Di Raimondo, Francesco

AU - Rossi, Davide

AU - Del Poeta, Giovanni

AU - Gaidano, Gianluca

AU - Shanafelt, Tait D.

AU - Gattei, Valter

N1 - Funding Information: 1Clinical and Experimental Onco-Hematology Unit, IRCCS Centro di Riferimento Oncologico, Aviano, Italy;2Division of Hematology – Department of Translational Medicine – Amedeo Avogadro University of Eastern Piedmont, Novara, Italy;3Division of Hematology, Ferrarotto Hospital, Catania, Italy;4Department of Hematology, Mayo Clinic, Rochester, MN, USA;5Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland;6IRCCS, Referral Cancer Center of Basilicata, Potenza, Italy;7Oncologia Medica A IRCCS, Centro di Riferimento Oncologico, Aviano, Italy;8Clinica Ematologica, Centro Trapianti e Terapie Cellulari "Carlo Melzi" DISM, Azienda Ospedaliera Universitaria S. Maria Misericordia, Udine, Italy; 9Department of Internal Medicine and Hematology, Maggiore General Hospital, University of Trieste, Italy and 10Division of Hematology, S. Eugenio Hospital and University of Tor Vergata, Rome, Italy Funding: supported in part by the Associazione Italiana Ricerca Cancro (AIRC), Investigator Grants IG-17622; Progetto Giovani Ricercatori no. GR-2011-02347441, no. GR-2011-02346826, no. GR-2011-02351370, Ministero della Salute, Rome, Italy; Ricerca clinica, traslazionale, di base, epidemiologica e organizzativa, Regione Friuli Venezia Giulia (“Linfo-Check” Project), Trieste, Italy; Associazione Italiana contro le Leucemie, linfomi e mielomi (AIL), Venezia Section, Pramaggiore Group, Italy; Fondazione per la Vita di Pordenone, Italy; 5x1000 Intramural Program, Centro di Riferimento Oncologico, Aviano, Italy.

PY - 2017/10/27

Y1 - 2017/10/27

UR - http://www.scopus.com/inward/record.url?scp=85032711919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032711919&partnerID=8YFLogxK

U2 - 10.3324/haematol.2017.170340

DO - 10.3324/haematol.2017.170340

M3 - Letter

AN - SCOPUS:85032711919

SN - 0390-6078

VL - 102

SP - e443-e446

JO - Haematologica

JF - Haematologica

IS - 11

ER -

Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this